Showing 1,221 - 1,240 results of 6,293 for search '"labelling"', query time: 0.09s Refine Results
  1. 1221
  2. 1222
  3. 1223

    Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context by Xiangyang Yu, Chujian Huang, Longde Du, Chunguang Wang, Yikun Yang, Xin Yu, Shengcheng Lin, Chenglin Yang, Hongbo Zhao, Songhua Cai, Zhe Wang, Lixu Wang, Xiaotong Guo, Baihua Zhang, Zhentao Yu, Jie He, Kai Ma

    Published 2025-01-01
    “…Methods: Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China. …”
    Get full text
    Article
  4. 1224

    Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial by Yu-Tian Xiao, Xianzhi Zhao, Yifan Chang, Xiaojun Lu, Ye Wang, Huojun Zhang, Shancheng Ren

    Published 2020-11-01
    “…We have designed this trial to investigate whether this combination, which theoretically maximises local control, is a safe and feasible approach for treating locally advanced prostate cancer.Methods and analysis This study is a phase I, open-label study to investigate the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy by a traditional 3+3 dose-escalation design with four planned radiation dose levels (39.6 Gy/22F, 45 Gy/25F, 50.4 Gy/28F and 54 Gy/30F). …”
    Get full text
    Article
  5. 1225

    Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy, and Single-Photon Emission Computed Tomography Using a Cyclic RGD Peptide Labeled with a Near-Infrared Fluorescent Dye and a Radionuclide by W. Barry Edwards, Walter J. Akers, Yunpeng Ye, Philip P. Cheney, Sharon Bloch, Baogang Xu, Richard Laforest, Samuel Achilefu

    Published 2009-03-01
    “…The in vivo distribution of 111 In-labeled LS308 in a 4t1 luc tumor-bearing mouse model was studied by fluorescence, bioluminescence, planar gamma, and single-photon emission computed tomography (SPECT). …”
    Get full text
    Article
  6. 1226
  7. 1227
  8. 1228
  9. 1229
  10. 1230

    Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk by Sarah Tonkin-Crine, Simon de Lusignan, Jienchi Dorward, Susan Hopkins, Gail Hayward, F D Richard Hobbs, Ly-Mee Yu, Oliver van Hecke, Julie Allen, Emma Ogburn, Christopher C Butler, Heather Rutter, Oghenekome Gbinigie, Sharon Tonner, Emily Bongard, Aleksandra Borek, Philip H Evans, Martin Llewelyn, Benjamin R Saville, Nicholas Berry, Hannah Swayze, David Judge, Jenna Grabey, Nicholas P B Thomas, Monique I Andersson, Mahendra Patel

    Published 2021-06-01
    “…Introduction There is an urgent need to idenfy treatments for COVID-19 that reduce illness duration and hospital admission in those at higher risk of a longer illness course and complications.Methods and analysis The Platform Randomised trial of INterventions against COVID-19 In older peoPLE trial is an open-label, multiarm, prospective, adaptive platform, randomised clinical trial to evaluate potential treatments for COVID-19 in the community. …”
    Get full text
    Article
  11. 1231
  12. 1232

    Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study by Yukari Kobayashi, Masaaki Sato, Kazuhiro Kakimi, Hirokazu Matsushita, Ryuji Suzuki, Takahiro Karasaki, Keita Masuzawa, Koji Nagaoka, Akihiro Hosoi, Shinnosuke Ikemura, Kentaro Kitano, Ichiro Kawada, Tadashi Manabe, Tomohiro Takehara, Toshiaki Ebisudani, Kazuhiro Nagayama, Yukio Nakamura, Hiroyuki Yasuda, Kenzo Soejima, Jun Nakajima

    Published 2020-10-01
    “…Here, we report the results of a phase 2 clinical trial of adoptive cell therapy using zoledronate-expanded autologous Vγ9Vδ2 T-cells for treatment-refractory NSCLC.Methods NSCLC patients who had undergone at least two regimens of standard chemotherapy for unresectable disease or had had at least one treatment including chemotherapy or radiation for recurrent disease after surgery were enrolled in this open-label, single-arm, multicenter, phase 2 study. After preliminary testing of Vγ9Vδ2 T-cell proliferation, autologous peripheral blood mononuclear cells were cultured with zoledronate and IL-2 to expand the Vγ9Vδ2 T-cells. …”
    Get full text
    Article
  13. 1233
  14. 1234
  15. 1235
  16. 1236
  17. 1237
  18. 1238
  19. 1239
  20. 1240